CX3CL1 — Fractalkine (C-X3-C Motif Chemokine Ligand 1)

Migration, Crosslink

📖

CX3CL1 — Fractalkine (C-X3-C Motif Chemokine Ligand 1)

active

wiki page Created: 2026-04-02T07:19:29 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-cx3cl1

📖 Wiki Page

gene1391 wordssynced 2026-04-02

CX3CL1 — Fractalkine (C-X3-C Motif Chemokine Ligand 1)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CX3CL1 — C-X3-C Motif Chemokine Ligand 1 (Fractalkine)</th>
</tr>
<tr> [@hundhausen2003]
<td class="label">Symbol</td> [@limatola2014]
<td><strong>CX3CL1</strong></td> [@lee2010]
</tr> [@bhaskar2010]
<tr> [@morganti2012]
<td class="label">Full Name</td> [@cardona2006a]
<td>C-X3-C Motif Chemokine Ligand 1 (Fractalkine / Neurotactin)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>16q13</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/6376" target="_blank">6376</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000006210" target="_blank">ENSG00000006210</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/601880" target="_blank">601880</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P78423" target="_blank">P78423</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), [Multiple Sclerosis](/diseases/multiple-sclerosis)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>[Neurons](/entities/neurons) ([cortex](/brain-regions/cortex), hippocampus), Endothelial cells, Dendritic cells</

...

CX3CL1 — Fractalkine (C-X3-C Motif Chemokine Ligand 1)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CX3CL1 — C-X3-C Motif Chemokine Ligand 1 (Fractalkine)</th>
</tr>
<tr> [@hundhausen2003]
<td class="label">Symbol</td> [@limatola2014]
<td><strong>CX3CL1</strong></td> [@lee2010]
</tr> [@bhaskar2010]
<tr> [@morganti2012]
<td class="label">Full Name</td> [@cardona2006a]
<td>C-X3-C Motif Chemokine Ligand 1 (Fractalkine / Neurotactin)</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>16q13</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/6376" target="_blank">6376</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000006210" target="_blank">ENSG00000006210</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/601880" target="_blank">601880</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P78423" target="_blank">P78423</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), [Multiple Sclerosis](/diseases/multiple-sclerosis)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>[Neurons](/entities/neurons) ([cortex](/brain-regions/cortex), hippocampus), Endothelial cells, Dendritic cells</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's" style="color:#ef9a9a">ALZHEIMER'S</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">AMYOTROPHIC LATERAL SCLEROSIS</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">237 edges</a></td>
</tr>
</table>

CX3CL1 — Fractalkine

Pathway Diagram

Mermaid diagram (expand to render)

Overview

CX3CL1 (C-X3-C Motif Chemokine Ligand 1), also known as fractalkine or neurotactin, encodes the sole member of the CX3C chemokine family. Located on chromosome 16q13, the gene produces a unique transmembrane chemokine that exists in both membrane-anchored and soluble forms, each with distinct signaling functions in the central nervous system[@harrison2012].

CX3CL1 is constitutively expressed at high levels by [neurons](/cell-types/neurons) throughout the brain, particularly in the cerebral cortex, [hippocampus](/brain-regions/hippocampus), [striatum](/brain-regions/striatum), and [thalamus](/brain-regions/thalamus). Its receptor, [CX3CR1](/genes/cx3cr1), is predominantly expressed on [microglia](/cell-types/microglia-neuroinflammation), establishing the CX3CL1–CX3CR1 axis as a primary mechanism of neuron–microglia communication[@paolicelli2014].

Dysregulation of CX3CL1 signaling has been implicated in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and other neurodegenerative conditions where aberrant microglial activation contributes to disease progression.

Gene Structure and Protein Products

Genomic Organization

The CX3CL1 gene spans approximately 15.5 kb on chromosome 16q13 and contains three exons. The promoter region contains binding sites for [NF-κB](/entities/nf-kb), AP-1, and CREB transcription factors, enabling activity-dependent and inflammation-responsive regulation of expression[@bhatt2018].

Protein Structure

The CX3CL1 protein (373 amino acids) has a distinctive domain architecture:

Chemokine domain (N-terminal): Contains the CX3C motif with three amino acids between the first two cysteines, enabling receptor binding and chemoattraction
Mucin-like stalk: A heavily glycosylated extended structure (~241 amino acids) that projects the chemokine domain away from the cell surface
Transmembrane domain: Anchors the protein in the plasma membrane
Cytoplasmic tail: Short intracellular domain involved in signaling and recycling

Membrane-Anchored vs. Soluble Forms

A critical feature of CX3CL1 biology is its dual existence:

Membrane-anchored CX3CL1: Functions as an adhesion molecule, mediating direct cell-cell contact between neurons and microglia. Promotes microglial quiescence and neuroprotection through tonic [CX3CR1](/genes/cx3cr1) signaling[@cardona2006].

Soluble CX3CL1 (sCX3CL1): Generated by proteolytic cleavage of the membrane form by [ADAM10](/genes/adam10) (constitutive) and [ADAM17](/genes/adam17)/TACE (inducible). Soluble fractalkine acts as a chemoattractant, recruiting microglia and monocytes to sites of neuronal injury[@hundhausen2003].

Function

Neuron–Microglia Communication

CX3CL1 serves as the primary "off" signal from neurons to microglia, maintaining microglial homeostasis in the healthy brain:

Microglial quiescence: Tonic CX3CL1–CX3CR1 signaling keeps microglia in a ramified, surveillance state with anti-inflammatory gene expression
Synaptic maintenance: CX3CL1 signaling regulates [microglial synaptic pruning](/mechanisms/microglial-synaptic-pruning-dysregulation), ensuring appropriate elimination of weak synapses during development and homeostatic plasticity[@paolicelli2014]
Phagocytic regulation: Modulates [microglial phagocytosis](/mechanisms/microglial-phagocytosis) of cellular debris, dead neurons, and protein aggregates
Inflammatory gating: Loss of CX3CL1 signaling disinhibits microglia, leading to excessive pro-inflammatory cytokine release including IL-1β, TNF-α, and IL-6

Neuroprotective Functions

CX3CL1 exerts direct and indirect neuroprotective effects:

Promotes neuronal survival through ERK1/2 and PI3K/[AKT](/genes/akt1) signaling in neurons
Enhances [BDNF](/genes/bdnf) release from microglia, supporting synaptic plasticity
Regulates glutamate receptor trafficking at synapses, preventing excitotoxicity
Modulates [neuroinflammation](/mechanisms/neuroinflammation) by restraining over-activated microglial responses[@limatola2014]

Chemotaxis and Immune Cell Recruitment

Soluble CX3CL1 functions as a potent chemoattractant:

Recruits CX3CR1+ microglia to sites of neuronal damage
Attracts peripheral monocytes across the [blood-brain barrier](/entities/blood-brain-barrier) during [neuroinflammation](/mechanisms/neuroinflammation)
Mediates NK cell and T cell recruitment in neuroinflammatory conditions

Disease Associations

Alzheimer's Disease

CX3CL1 plays a complex, context-dependent role in [Alzheimer's disease](/diseases/alzheimers-disease):

Amyloid pathology: CX3CR1 knockout in [APP](/entities/app-protein) transgenic mice reduces [amyloid-beta](/proteins/amyloid-beta) deposition by enhancing microglial phagocytic activity, suggesting CX3CL1 normally restrains amyloid clearance[@lee2010]
[Tau](/proteins/tau) pathology: Conversely, CX3CR1 deficiency in tau transgenic mice exacerbates [tau hyperphosphorylation](/mechanisms/tau-hyperphosphorylation) and neurodegeneration, indicating CX3CL1 signaling protects against tau-mediated toxicity[@bhaskar2010]
Biomarker potential: CSF soluble CX3CL1 levels are elevated in early AD and correlate with tau but not amyloid-beta levels, suggesting utility as a neuroinflammation biomarker
Genetic variants: The CX3CR1 V249I/T280M haplotype affects receptor function and has been associated with modified AD risk in some populations

Parkinson's Disease

In [Parkinson's disease](/diseases/parkinsons-disease), CX3CL1 modulates [dopaminergic neuron](/cell-types/dopaminergic-neurons) vulnerability:

Loss of CX3CL1 signaling enhances [MPTP](/therapeutics/mptp-model)-induced dopaminergic neuron death through excessive microglial activation
CX3CL1 overexpression in [substantia nigra](/brain-regions/substantia-nigra) protects dopaminergic neurons in toxin models
Soluble CX3CL1 injection into the striatum reduces neuroinflammation and neuronal loss in 6-OHDA models[@morganti2012]
[Alpha-synuclein](/proteins/alpha-synuclein) aggregates downregulate neuronal CX3CL1 expression, creating a feed-forward loop of microglial activation

Amyotrophic Lateral Sclerosis

In [ALS](/diseases/amyotrophic-lateral-sclerosis):

CX3CL1 levels decline in the spinal cord during disease progression in [SOD1](/entities/sod1) mutant mice
CX3CR1 deficiency accelerates motor neuron loss and disease onset in SOD1-G93A mice
Fractalkine signaling modulates the transition from neuroprotective to neurotoxic microglial phenotypes[@cardona2006a]

Multiple Sclerosis

CX3CL1 is expressed on endothelial cells at the blood-brain barrier and regulates immune cell transmigration
Elevated CSF CX3CL1 correlates with disease activity and relapse in relapsing-remitting MS

Expression

Brain Distribution

CX3CL1 shows a distinctive pattern of neuronal expression in the brain:

Cerebral cortex: Layers II/III and V pyramidal neurons show high expression
Hippocampus: Abundant in CA1-CA3 pyramidal neurons and dentate gyrus granule cells
Striatum: Medium spiny neurons express CX3CL1
Thalamus: Multiple thalamic nuclei show moderate expression
Substantia nigra: Dopaminergic neurons express CX3CL1
Spinal cord: Motor neurons express CX3CL1 constitutively

Expression data from the [Allen Brain Atlas](https://portal.brain-map.org/) confirms widespread neuronal expression with regional variation correlating with vulnerability to neurodegeneration.

Regulation of Expression

CX3CL1 expression is regulated by:

Neuronal activity: Glutamate receptor activation upregulates CX3CL1 via CREB-dependent transcription
Inflammation: TNF-α and IL-1β increase CX3CL1 expression via NF-κB, potentially as a compensatory anti-inflammatory response
Hypoxia: HIF-1α activation induces CX3CL1 in neurons and endothelial cells
Aging: CX3CL1 expression declines with age, particularly in the hippocampus, potentially contributing to age-related neuroinflammation

Therapeutic Implications

CX3CL1 as Therapeutic Target

The CX3CL1–CX3CR1 axis presents opportunities for therapeutic intervention:

Recombinant fractalkine: Administration of soluble CX3CL1 protects neurons in preclinical models of AD, PD, and stroke

Gene therapy: AAV-mediated CX3CL1 overexpression in the CNS reduces neuroinflammation in mouse models

Small molecule CX3CR1 modulators: Being developed for precise modulation of microglial activation state

Biomarker development: CSF and plasma sCX3CL1 as markers of microglial activation and neuron-microglia interaction status

Challenges

The dual role of CX3CL1 in amyloid (promoting) vs. tau (protective) pathology complicates therapeutic strategies in AD
Systemic CX3CR1 blockade could affect peripheral immune surveillance
Timing of intervention is critical: CX3CL1 augmentation may be beneficial early but less effective in late-stage disease

Key Publications

[Harrison et al., Role for fractalkine/CX3CL1 in the biology of neurodegenerative diseases (2012)](https://pubmed.ncbi.nlm.nih.gov/22500670/)

[Paolicelli et al., Fractalkine regulation of microglial physiology and consequences on the brain and behavior (2014)](https://pubmed.ncbi.nlm.nih.gov/24434769/)

[Limatola & Bhatt, Chemokine CX3CL1 protects neuron–glia communication (2014)](https://pubmed.ncbi.nlm.nih.gov/24462664/)

External Links

[NCBI Gene: CX3CL1](https://www.ncbi.nlm.nih.gov/gene/6376)
[UniProt: P78423](https://www.uniprot.org/uniprot/P78423)
[OMIM: 601880](https://omim.org/entry/601880)
[GeneCards: CX3CL1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CX3CL1)
[Allen Brain Atlas: CX3CL1](https://portal.brain-map.org/)

References

[Harrison et al., Role for fractalkine/CX3CL1 in the biology of neurodegenerative diseases (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22500670/)

[Paolicelli et al., Fractalkine regulation of microglial physiology and consequences on the brain and behavior (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24434769/)

[Bhatt et al., Transcriptional regulation of CX3CL1 gene promoter (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29427570/)

[Cardona et al., Control of microglial neurotoxicity by the fractalkine receptor (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16998468/)

[Hundhausen et al., The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12697768/)

[Unknown, Limatola & Bhatt, Chemokine CX3CL1 protects neuron–glia communication in the nervous system (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24462664/)

[Lee et al., CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20660255/)

[Bhaskar et al., Regulation of tau pathology by the microglial fractalkine receptor (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20838685/)

[Morganti et al., The soluble isoform of CX3CL1 is necessary for neuroprotection in a mouse model of Parkinson's disease (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22508956/)

[Cardona et al., Control of microglial neurotoxicity by the fractalkine receptor (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16998468/)

Pathway Diagram

The following diagram shows the key molecular relationships involving CX3CL1 — Fractalkine (C-X3-C Motif Chemokine Ligand 1) discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

CX3CL1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-cx3cl1
kg_node_id	CX3CL1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-1f473fb48b87
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-cx3cl1'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

318

Outgoing

327

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

CX3CL1 — Fractalkine (C-X3-C Motif Chemokine Ligand 1)

CX3CL1 — Fractalkine (C-X3-C Motif Chemokine Ligand 1)

CX3CL1 — Fractalkine (C-X3-C Motif Chemokine Ligand 1)

CX3CL1 — Fractalkine

Pathway Diagram

Overview

Gene Structure and Protein Products

Genomic Organization

Protein Structure

Membrane-Anchored vs. Soluble Forms

Function

Neuron–Microglia Communication

Neuroprotective Functions

Chemotaxis and Immune Cell Recruitment

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Multiple Sclerosis

Expression

Brain Distribution

Regulation of Expression

Therapeutic Implications

CX3CL1 as Therapeutic Target

Challenges

Key Publications

See Also

External Links

References

Pathway Diagram

💬 Discussion